Bluebird Bio Closes $30M Venture Round
Cambridge, Mass.-based Bluebird Bio, which is developing gene therapies for genetic disorders, has inked $30 million in fresh capital from investors including ARCH Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group. ARCH Venture Partners was a new investor in the company, and the firm’s managing director Steven Gillis will join Bluebird Bio’s board. The company completed a $35 million Series B in early 2010.
20 April 2011•3 mins read
